resTORbio (NASDAQ: TORC) is one of 490 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare resTORbio to similar companies based on the strength of its institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.
Valuation and Earnings
This table compares resTORbio and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|resTORbio Competitors||$2.01 billion||$136.35 million||-3.57|
resTORbio’s peers have higher revenue and earnings than resTORbio. resTORbio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent ratings and price targets for resTORbio and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
resTORbio currently has a consensus price target of $29.25, indicating a potential upside of 232.76%. As a group, “Pharmaceutical preparations” companies have a potential upside of 41.86%. Given resTORbio’s stronger consensus rating and higher probable upside, analysts plainly believe resTORbio is more favorable than its peers.
This table compares resTORbio and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
39.3% of resTORbio shares are held by institutional investors. Comparatively, 48.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.1% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
resTORbio beats its peers on 7 of the 12 factors compared.
resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts. resTORbio, Inc. is a subsidiary of PureTech Health plc.
Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.